Search Results - "Zhao, Carol"

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension by Benza, Raymond L., Kanwar, Manreet K., Raina, Amresh, Scott, Jacqueline V., Zhao, Carol L., Selej, Mona, Elliott, C. Greg, Farber, Harrison W.

“…Achievement of low-risk status is a treatment goal in pulmonary arterial hypertension (PAH). Risk assessment often is performed using multiparameter tools,…”
Get full text

The Addition of a Nonsteroidal Anti-inflammatory Drug in Local Infiltration Analgesia During Total Knee Arthroplasty Increases the Risk of Acute Kidney Injury in Patients Who Have Renal Impairment: A Propensity-Matched Retrospective Cohort Study by Chee, Brian R.K., Quah, Emrick S.H., Zhao, Carol X.S., Tan, Kelvin G.P., Thwin, Lynn

“…Local infiltration analgesia (LIA) is a crucial component of pain management during total knee arthroplasty (TKA), Nonsteroidal anti-inflammatory drugs…”
Get full text

Risk stratification in pulmonary arterial hypertension using Bayesian analysis by Kanwar, Manreet K, Gomberg-Maitland, Mardi, Hoeper, Marius, Pausch, Christine, Pittrow, David, Strange, Geoff, Anderson, James J, Zhao, Carol, Scott, Jacqueline V, Druzdzel, Marek J, Kraisangka, Jidapa, Lohmueller, Lisa, Antaki, James, Benza, Raymond L

“…Current risk stratification tools in pulmonary arterial hypertension (PAH) are limited in their discriminatory abilities, partly due to the assumption that…”
Get full text

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial by Perez, Edith A, Dr, Awada, Ahmad, MD, O'Shaughnessy, Joyce, MD, Rugo, Hope S, MD, Twelves, Chris, MD, Im, Seock-Ah, MD, Gómez-Pardo, Patricia, MD, Schwartzberg, Lee S, MD, Diéras, Veronique, MD, Yardley, Denise A, MD, Potter, David A, MD, Mailliez, Audrey, MD, Moreno-Aspitia, Alvaro, MD, Ahn, Jin-Seok, MD, Zhao, Carol, MS, Hoch, Ute, PhD, Tagliaferri, Mary, MD, Hannah, Alison L, MD, Cortes, Javier, MD

“…Summary Background New options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I inhibitor…”
Get full text

Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis by Chakinala, Murali M., Coyne, Daniel W., Benza, Raymond L., Frost, Adaani E., McGoon, Michael D., Hartline, Brian K., Frantz, Robert P., Selej, Mona, Zhao, Carol, Mink, David R., Farber, Harrison W.

“…Renal dysfunction is associated with abnormal cardiopulmonary hemodynamics, in-hospital death and poor survival in patients with pulmonary arterial…”
Get full text

3D printing for preoperative planning and intraoperative surgical jigs - A prospective study on surgeon perception by Zhao, Carol Xiaoshu, Yam, Michael

“…Patient-specific 3D printed models have been widely used as a complement to 2D imaging for preoperative planning in orthopaedic surgery. This study discusses…”
Get full text

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study by Awada, Ahmad, Dr Prof, Garcia, Agustin A, MD, Chan, Stephen, MD, Jerusalem, Guy H M, Prof, Coleman, Robert E, Prof, Huizing, Manon T, Prof, Mehdi, Aminder, MD, O'Reilly, Sue M, MD, Hamm, John T, MD, Barrett-Lee, Peter J, Prof, Cocquyt, Veronique, Prof, Sideras, Kostandinos, MD, Young, David E, MD, Zhao, Carol, MS, Chia, Yen Lin, PhD, Hoch, Ute, PhD, Hannah, Alison L, MD, Perez, Edith A, Prof

“…Summary Background New therapeutic options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I…”
Get full text

Firms' heterogeneity, demand accumulating, and exchange rate pass-through by Tan, Yong, Zhao, Chen Carol

“…In this article, we study how the export behaviors of new and incumbent exporters differentially respond to exchange rate shocks. We establish a dynamic model,…”
Get full text

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer by VERGOTE, Ignace B, GARCIA, Agustin, ARMENIO, Vincent A, DUSKA, Linda, POOLE, Chris, GENNIGENS, Christine, DIRIX, Luc Y, LEUNG, Abraham C. F, ZHAO, Carol, SOUFI-MAHJOUBI, Raoudha, RUSTIN, Gordon, MICHA, John, PIPPITT, Charles, BENDELL, Johanna, SPITZ, Daniel, REED, Nicholas, DARK, Graham, FRACASSO, Paula M, IBRAHIM, Emad N

“…Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the…”
Get full text

Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries by Kim, Nick H., Fisher, Micah, Poch, David, Zhao, Carol, Shah, Mehul, Bartolome, Sonja

“…Limited data about the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class…”
Get full text

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting by Frantz, Robert P., Chin, Kelly M., Zhao, Carol, Flynn, Megan, Badesch, David

“…Patient-reported outcomes are important measures to include in pulmonary arterial hypertension clinical trials but are not widely utilized in clinical…”
Get full text

Role of patient specific 3D printed models in patient confidence, understanding and satisfaction of care in Singapore by Zhao, Carol Xiaoshu, Yam, Michael

“…Patient specific 3D models have been widely used for pre-op planning and intra-op guidance in orthopaedic surgery. These models however are not often used in…”
Get full text

Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry by Medrek, Sarah, Sahay, Sandeep, Zhao, Carol, Selej, Mona, Frost, Adaani

“…Prior research has suggested that the prevalence and outcomes of pulmonary arterial hypertension (PAH) may vary by race or ethnicity. However, these studies…”
Get full text

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries by Khanna, Dinesh, Zhao, Carol, Saggar, Rajan, Mathai, Stephen C., Chung, Lorinda, Coghlan, J. Gerry, Shah, Mehul, Hartney, John, McLaughlin, Vallerie

“…Objective Data on the magnitude of benefit of modern therapies for pulmonary arterial hypertension (PAH) in connective tissue disease (CTD)–associated PAH are…”
Get full text

Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension by El-Kersh, Karim, Zhao, Carol, Elliott, Gregory, Farber, Harrison W., Gomberg-Maitland, Mardi, Selej, Mona, Garcia-Ferrer, Josephine, Benza, Raymond

“…Multiparametric risk assessment tools determine mortality risk in patients with pulmonary arterial hypertension (PAH) by combining invasive and noninvasive…”
Get full text

Smoking history and pulmonary arterial hypertension: Demographics, onset, and outcomes by Frost, Adaani E., Zhao, Carol, Farber, Harrison W., Benza, Raymond, Yen, Joseph, Selej, Mona, Elliott, C. Gregory

“…Smoking prevalence and its association with pulmonary arterial hypertension (PAH) outcomes have not been described in patients in the United States. Using the…”
Get full text

CLINICAL CHARACTERISTICS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND TREATMENT PATTERNS: A REAL-WORLD ANALYSIS FROM SPHERE (SELEXIPAG: THE USERS DRUG REGISTRY) by MCLAUGHLIN, VALLERIE, CHIN, KELLY, FARBER, HARRISON, CHAKINALA, MURALI, HIGHLAND, KRISTIN, HEMNES, ANNA, ZHAO, CAROL, NARAYAN, VEENA, KIM, NICK

Get full text

REAL-WORLD DATA FOR SELEXIPAG IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A SPHERE (SELEXIPAG: THE USERS DRUG REGISTRY) ANALYSIS by Chin, Kelly, Chakinala, Murali, Hemnes, Anna, Farber, Harrison, McLaughlin, Vallerie, Kim, Nick, Zhao, Carol, Narayan, Veena, Highland, Kristin

Get full text

MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL by SAFDAR, ZEENAT, JANSA, PAVEL, MEHTA, SANJAY, PULIDO-ZAMUDIO, TOMAS, K SASTRY, B, SITBON, OLIVIER, SOUZA, ROGERIO, TORBICKI, ADAM, MARTINEZ, ELIANA, ZHAO, CAROL, DELCROIX, MARION

Get full text

DEVELOPMENT OF A SIMPLIFIED RISK CALCULATOR FOR STRATIFYING PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION BASED ON ECHOCARDIOGRAPHIC PARAMETERS IN THE REVEAL DATABASE by EL-KERSH, KARIM, ZHAO, CAROL, ELLIOTT, C, FARBER, HARRISON, GOMBERG MAITLAND, MARDI, SELEJ, MONA, GARCIA-FERRER, JOSEPHINE, BENZA, RAYMOND

Get full text